Wyden: NIH ignored patient, taxpayer costs for Taxol. (NIH).
Publication: Medicine & Health
Publication Date: 16-JUN-03
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
The National Institutes of Health had the authority to get a better deal for taxpayers and patients when it negotiated rights for the cancer drug Taxol, whose development relied heavily on NIH research. But the agency didn't use its clout to full advantage. That's the finding of a General Accounting Office analysis released by Sen. Ron Wyden (D-OR) June 6.
NIH's agreement allowing Bristol-Myers Squibb to patent the drug netted only $35 million in royalties for the government and failed to ensure that federally insured...
Read the full article for free courtesy of your local library.
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
